Screening for cerebrale arteriovenøsemalformationer ved mb. Osler

Simon Kjær Simonsen; Troels Halfeld Nielsen; Rikke Beese Dalby; Annette Dam Fialla; Bibi Lange; Pernille M Tørring; Anabel Diaz; Anette Drøhse Kjeldsen

Screening for cerebrale arteriovenøsemalformationer ved mb. Osler

Simon Kjær Simonsen, Troels Halfeld Nielsen, Rikke Beese Dalby, Annette Dam Fialla, Bibi Lange, Pernille M Tørring, Anabel Diaz, Anette Drøhse Kjeldsen

Aarhus Universitetshospital

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstrakt

Patients with hereditary haemorrhagic telangiectasia (HHT) are known to suffer from cerebral arteriovenous malformations (CAVMs). In this review, we explore existing literature for bleeding risk, interventional therapy and neuroradiological features in HHT-related CAVMs. Studies estimate the annual intracerebral haemorrhage rate of CAVMs in HHT patients to be 0.667-1.014%. The clinician must balance bleeding risk and the non-negligible procedural risks of interventional therapy. We recommend, in agreement with European guidelines, that screening of asymptomatic HHT patients should only be carried out after careful information.

Bidragets oversatte titel	Screening for cerebral arteriovenous malformations in patients with hereditary haemorrhagic telangiectasia
Originalsprog	Dansk
Artikelnummer	V12200905
Tidsskrift	Ugeskrift for Læger
Vol/bind	183
Udgave nummer	19
ISSN	0041-5782
Status	Udgivet - 17. maj 2021

Dokumenter og links

https://ugeskriftet.dk/videnskab/screening-cerebrale-arteriovenosemalformationer-ved-mb-osler

Citationsformater

@article{470fd07b998841b3b122b82f189bd079,

title = "Screening for cerebrale arterioven{\o}semalformationer ved mb. Osler",

abstract = "Patients with hereditary haemorrhagic telangiectasia (HHT) are known to suffer from cerebral arteriovenous malformations (CAVMs). In this review, we explore existing literature for bleeding risk, interventional therapy and neuroradiological features in HHT-related CAVMs. Studies estimate the annual intracerebral haemorrhage rate of CAVMs in HHT patients to be 0.667-1.014%. The clinician must balance bleeding risk and the non-negligible procedural risks of interventional therapy. We recommend, in agreement with European guidelines, that screening of asymptomatic HHT patients should only be carried out after careful information.",

author = "{Kj{\ae}r Simonsen}, Simon and Nielsen, {Troels Halfeld} and Dalby, {Rikke Beese} and {Dam Fialla}, Annette and Bibi Lange and T{\o}rring, {Pernille M} and Anabel Diaz and Kjeldsen, {Anette Dr{\o}hse}",

year = "2021",

month = may,

day = "17",

language = "Dansk",

volume = "183",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "19",

}

TY - JOUR

T1 - Screening for cerebrale arteriovenøsemalformationer ved mb. Osler

AU - Kjær Simonsen, Simon

AU - Nielsen, Troels Halfeld

AU - Dalby, Rikke Beese

AU - Dam Fialla, Annette

AU - Lange, Bibi

AU - Tørring, Pernille M

AU - Diaz, Anabel

AU - Kjeldsen, Anette Drøhse

PY - 2021/5/17

Y1 - 2021/5/17

N2 - Patients with hereditary haemorrhagic telangiectasia (HHT) are known to suffer from cerebral arteriovenous malformations (CAVMs). In this review, we explore existing literature for bleeding risk, interventional therapy and neuroradiological features in HHT-related CAVMs. Studies estimate the annual intracerebral haemorrhage rate of CAVMs in HHT patients to be 0.667-1.014%. The clinician must balance bleeding risk and the non-negligible procedural risks of interventional therapy. We recommend, in agreement with European guidelines, that screening of asymptomatic HHT patients should only be carried out after careful information.

AB - Patients with hereditary haemorrhagic telangiectasia (HHT) are known to suffer from cerebral arteriovenous malformations (CAVMs). In this review, we explore existing literature for bleeding risk, interventional therapy and neuroradiological features in HHT-related CAVMs. Studies estimate the annual intracerebral haemorrhage rate of CAVMs in HHT patients to be 0.667-1.014%. The clinician must balance bleeding risk and the non-negligible procedural risks of interventional therapy. We recommend, in agreement with European guidelines, that screening of asymptomatic HHT patients should only be carried out after careful information.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 183

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 19

M1 - V12200905

ER -

Screening for cerebrale arteriovenøsemalformationer ved mb. Osler

Abstrakt

Dokumenter og links

Fingeraftryk

Citationsformater